Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 1/20 | 0.50 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 8/20 | 0.44 |
| ▸ | MMP3 | P08254 | 7/20 | 0.44 |
| ▸ | MMP7 | P09237 | 5/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.43 |
| ▸ | FCER2 | P06734 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7677459 | 0.89 | MMP2 (0.47) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL7680524 | 0.89 | MMP2 (0.47) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL7079011 | 0.83 | HDAC3 (0.41) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL7654835 | 0.81 | MMP2 (0.59) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL7118116 | 0.80 | CTSK (0.52) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL7112357 | 0.80 | CTSK (0.52) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL7883062 | 0.80 | MMP2 (0.70) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL7883057 | 0.80 | MMP2 (0.70) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL4422495 | 0.80 | MMP2 (0.70) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL13696746 | 0.80 | MMP2 (0.70) | MMP2MMP9ANPEPLTA4HLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6476067-B1 | N-formyl hydroxylamine derivatives as antibacterial agents | BRITISH BIOTECH (GB) | 2002-11-05 | — | — | US | claimed |
| EP-1140058-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2003-11-05 | — | — | EP | disclosed |
| US-20030149084-A1 | Cytostatic agents | AYSCOUGH ANDREW PAUL (GB) | 2003-08-07 | — | — | US | disclosed |
| US-6495597-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-12-17 | — | — | US | disclosed |
| US-6476067-B1 | N-formyl hydroxylamine derivatives as antibacterial agents | BRITISH BIOTECH (GB) | 2002-11-05 | — | — | US | disclosed |
| EP-1146868-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-10-24 | — | — | EP | disclosed |
| EP-1140058-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-10-10 | — | — | EP | disclosed |
| EP-1054861-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000043001-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000035440-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999041232-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149084-A1 | Cytostatic agents | MCTS1, NNMT, MMP12 | MMP2 6/4885MMP9 36/4885ANPEP 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.